GlassScriptPhysician profile
Douglas Pennington
NPI 1891714580
$10,473.13
in general payments reported to CMS, 2019-2025
57 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $800 · 2021: $2,032 · 2022: $1,701 · 2023: $2,055 · 2024: $1,448 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,678.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,115.48 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,048.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $808.58 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $605.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $527.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $503.55 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $449.04 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.27 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $339.16 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $331.61 | 2019-2025 | Veozah |
| Medtronic, INC. | $305.93 | 2023-2024 | Synchromedii, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.74 | 2019-2025 | Xifaxan |
| Daiichi Sankyo INC. | $195.79 | 2020-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $172.56 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.